top of page

"Liver NETs: Understanding Liver-Directed Therapies and PRRT"



Some Topics Covered: Neuroendocrine tumors (NETs), liver metastases, liver-directed therapies, peptide receptor radionuclide therapy (PRRT), NET treatment, neuroendocrine cancer



ABOUT


Join us for an overview of liver-directed therapies and peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors involving the liver. Presented by a physician with expertise in both interventional radiology and nuclear medicine, this webinar will explore how treatment decisions are made, when different approaches may be considered, and how these therapies may fit into an overall treatment plan.



ABOUT DR. GABRIEL FINE



Gabriel Fine, M.D.

Interventional & Nuclear Medicine Radiologist

Nuclear Medicine

City of Hope Cancer Center Duarte, California





Gabriel Fine, M.D., is an Associate Professor of Diagnostic Radiology in the Division of Nuclear Medicine at City of Hope Cancer Center. He is an internationally recognized leader in precision therapeutics, with specialized expertise in theranostics, molecular imaging, and interventional oncology. ABR board certified in Interventional Radiology/Diagnostic Radiology and Nuclear Radiology, Dr. Fine advances precision oncology through the integration of advanced imaging, image-guided intervention, and radioligand-based therapies.

Dr. Fine has played a defining role in the development and expansion of theranostics programs, advancing the clinical integration of molecular imaging and radioligand therapies within multidisciplinary cancer care. His work focuses on improving diagnostic accuracy, refining therapeutic selection, and developing biologically informed approaches that enhance efficacy while minimizing treatment-related toxicity.


Fine's academic work is distinguished by a sustained emphasis on translational innovation at the intersection of molecular imaging, image-guided intervention, and artificial intelligence. He has helped develop novel approaches in computational imaging and procedural technologies, supported by an extensive patent portfolio—spanning artificial intelligence, image-based diagnostics, procedural navigation, and interventional platforms. He is the author of numerous peer-reviewed publications and scientific abstracts spanning molecular imaging, interventional oncology, and emerging applications of artificial intelligence in image-guided medicine.


Dr. Fine received his Bachelor of Arts in Neuroscience from Carleton College and his medical degree from the University of Washington School of Medicine. During medical school, he was selected for a cardiovascular research fellowship through the Sarnoff Cardiovascular Research Foundation, conducting research at Massachusetts General Hospital and Brigham and Women’s Hospital. He completed his radiology residency at the University of Washington, followed by fellowship training in interventional radiology at Memorial Sloan Kettering Cancer Center / New York-Presbyterian Hospital.


Dr. Fine is deeply committed to mentorship, actively fostering the professional development of residents, fellows, and junior faculty. His teaching philosophy prioritizes patient-centered care, seamlessly integrating advanced imaging, procedural innovation, and precision therapeutics to cultivate the next generation of clinician–scientists, innovators, and clinical leaders.


His contributions to academic medicine have been recognized through election to the Alpha Omega Alpha Honor Medical Society, induction into the Sigma Xi Scientific Research Honor Society, the Frederick A. Mann Endowed Award, the JVIRĀ Editor’s Award for Outstanding Laboratory Investigation—for which Dr. Fine served as senior author—and additional distinctions for research, teaching, and clinical excellence.


Dr. Fine delivers patient-centered care grounded in precision, clarity, and evidence-based decision-making.Ā 



Ā THANKS TO OUR SPONSORS








The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

NEUROENDOCRINE CANCER FOUNDATION
 
Mailing Address:
PO BOX 370466
DENVER, CO 80237

info@ncf.net
​
  • Facebook
  • Instagram
  • X
  • Youtube
  • LinkedIn

© 2026 by Neuroendocrine Cancer Foundation

bottom of page